41. Early learning and child care: agencies have helped address fragmentation and overlap through improved coordination : report to the Chairwoman, Committee on Education and the Workforce, House of Representatives
Search Results
42. Medicare: CMS should evaluate providing coverage for disposable medical devices that could substitute for durable medical equipment : report to Congressional committees
43. Early learning and child care: overview of federal investment and agency coordination : testimony before the Subcommittee on Early Childhood, Elementary, and Secondary Education, Committee on Education and the Workforce, House of Representatives
44. Public health information technology: HHS has made little progress toward implementing enhanced situational awareness network capabilities : report to Congressional committees
45. Personal firearms: programs that promote safe storage and research on their effectiveness : report to Congressional requesters
46. Human trafficking: investigations in Indian country or involving Native Americans and actions needed to better report on victims served : testimony before the Committee on Indian Affairs, U.S. Senate
47. Newborn health: federal action needed to address neonatal abstinence syndrome : report to Congressional addressees
48. Biodefense: federal efforts to develop biological threat awareness : report to Congressional requesters
49. Part D plans generally include drugs commonly used by dual eligibles: 2017
50. Health document submission requirements for tobacco products: (revised)
51. Registration and product listing for owners and operators of domestic tobacco product establishments: (revised)
52. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment
53. Regulatory classification of pharmaceutical co-crystals
54. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment
55. How to prepare a pre-request for designation (pre-RFD)
56. Migraine: developing drugs for acute treatment
57. Q11 development and manufacture of drug substances (chemical entities and biotechnological/biological entities): questions and answers
58. E6(R2) good clinical practice: integrated addendum to ICH E6(R1)
59. M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk
60. E18 genomic sampling and management of genomic data
